Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.6 (
RNA polymerase
)
34,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Reversible phosphorylation of
RNA polymerase
(RNAP) II's largest subunit C-terminal domain (CTD) is a key event during mRNA metabolism. The CTD phosphatase, FCP1, catalyzes the dephosphorylation of RNAP II and is thought to play a major role in polymerase recycling. In this study, we isolated a novel phosphatase gene by large-scale sequencing analysis of a human fetal brain cDNA library. Its cDNA is 2215 bp in length, encoding a 318-amino acid polypeptide that contains a ubiquitin-like domain and a CTD phosphatase domain. Therefore, it was termed
ubiquitin-like domain containing CTD phosphatase 1
(
UBLCP1
). Reverse transcription PCR (RT-PCR) revealed that
UBLCP1
was expressed with relatively lower levels in most adult normal tissues and higher levels in fast growing or tumor tissues. Transient transfection experiment suggested that
UBLCP1
was localized in the nucleus of COS-7 cells. Significantly,
UBLCP1
could dephosphorylate GST-CTD in vitro. Accordingly,
UBLCP1
may play a role in the regulation of phosphorylation state of
RNA polymerase II
C-terminal domain.
...
PMID:Cloning and characterization of a novel RNA polymerase II C-terminal domain phosphatase. 1588 30